CLDN18 and gastroesophageal junction adenocarcinoma: CLDN18 expression tested by IHC has already entered daily clinical practice for selecting patients with locally advanced and metastatic gastric and gastroesophageal junction adenocarcinomas for anti-CLDN18.2-targeted therapy [22].